ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

LTRN Lantern Pharma Inc

5.77
-0.22 (-3.67%)
Apr 18 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 107,146
Bid Price 5.53
Ask Price 5.75
News -
Day High 6.13

Low
2.38

52 Week Range

High
11.99

Day Low 5.75
Company Name Stock Ticker Symbol Market Type
Lantern Pharma Inc LTRN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.22 -3.67% 5.77 20:00:00
Open Price Low Price High Price Close Price Prev Close
5.92 5.75 6.13 5.77 5.99
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,194 107,146 $ 5.92 $ 634,017 - 2.38 - 11.99
Last Trade Time Type Quantity Stock Price Currency
19:55:50 10 $ 5.75 USD

Lantern Pharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
63.58M 10.87M - 0 -15.96M -1.47 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Lantern Pharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No LTRN Message Board. Create One! See More Posts on LTRN Message Board See More Message Board Posts

Historical LTRN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week7.337.6255.356.28227,263-1.56-21.28%
1 Month8.9611.995.358.45301,995-3.19-35.60%
3 Months4.2811.993.857.43327,5621.4934.81%
6 Months3.3611.992.386.94175,1172.4171.73%
1 Year5.0211.992.386.60103,8930.7514.94%
3 Years15.3316.9452.387.7870,060-9.56-62.36%
5 Years15.1624.842.3810.2876,229-9.39-61.94%

Lantern Pharma Description

Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves four drug candidates and an Antibody Drug Conjugate (ADC) program directed towards eight therapeutic targets. Its A.I. platform, known as RADR, includes more than 18 billion data points, and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds.

Your Recent History

Delayed Upgrade Clock